Anders Waage
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 105
- Immunology top 0.5%
- Immune Response and Inflammation 20
- Oncology top 1%
- Bone health and treatments 14
- Cancer Treatment and Pharmacology 13
- Microbiology top 0.5%
- Hepatology top 2%
- Liver physiology and pathology 16
-
- Protein Degradation and Inhibitors 24
- Ubiquitin and proteasome pathways 10
- Bone Metabolism and Diseases 9
Anders Waage
171 papers receiving 9.6k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Hematology 3.0k
- Immunology 2.9k
- Oncology 2.4k
- Microbiology 511
- Hepatology 423
Countries citing papers authored by Anders Waage
This map shows the geographic impact of Anders Waage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Waage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Waage more than expected).
Fields of papers citing papers by Anders Waage
This network shows the impact of papers produced by Anders Waage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Waage. The network helps show where Anders Waage may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anders Waage, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 3 | |
| 5 | 2022 | 34 | |
| 6 | 2021 | 92 | |
| 7 | Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial | 2017 | 0 |
| 8 | 2016 | 10 | |
| 9 | 2013 | 21 | |
| 10 | 2011 | 179 | |
| 11 | A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity | 2008 | 16 |
| 12 | Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 2002 | 2 |
| 13 | 2002 | 45 | |
| 14 | Talassemi og sigdcellesykdom i Norge | 2001 | 0 |
| 15 | 2000 | 38 | |
| 16 | 1996 | 122 | |
| 17 | 1993 | 48 | |
| 18 | 1990 | 191 | |
| 19 | 1989 | 398 | |
| 20 | 1987 | 174 |
About Anders Waage
Anders Waage is a scholar working on Hematology, Oncology and Hepatology, having authored 179 papers that have together received 9.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (105 papers), Protein Degradation and Inhibitors (24 papers), Immune Response and Inflammation (20 papers), Liver physiology and pathology (16 papers), Bone health and treatments (14 papers), Cancer Treatment and Pharmacology (13 papers), Ubiquitin and proteasome pathways (10 papers) and Bone Metabolism and Diseases (9 papers). The work is most often cited by research in Hematology (3.0k citations), Immunology (2.9k citations) and Oncology (2.4k citations). Anders Waage has collaborated with scholars based in Norway, Denmark and Sweden. Frequent co-authors include Terje Espevik, Alfred Halstensen, Anders Sundan, Magne Børset, P Brandtzæg, Peter Kierulf, Carina Seidel, Henrik Hjorth‐Hansen, Refaat Shalaby and M R Shalaby. Their work appears in journals such as Blood, European Journal Of Haematology, British Journal of Haematology, Oncotarget and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.